AKBA · Akebia Therapeutics, Inc. · Webcasts, Transcripts & Audio
$0.42
+0.01 (+3.28%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$117.26M
Shares
277.66M
Volume · Nov 19
2.75M
Avg daily vol (3M)
8.17M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Akebia Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Akebia Therapeutics, Inc. (AKBA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Akebia Therapeutics, Inc. (AKBA) Q3 2026 Earnings Call Transcript
Positive tone
Large dialysis provider adoption
VOICE outcomes data
VOCAL study
Revenue
$36.90M
▼ 37.2% YoY Diluted EPS
$-0.05
Gross margin
82.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-05
Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript
Confident tone
Pipeline: Prolisiguat (PROLI) in FSGS
Pipeline: Ibribifus (EBRI) in rare kidney diseases
VOICE trial results
Revenue
$49.13M
▼ 21.4% YoY Diluted EPS
$-0.03
Gross margin
78.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Akebia Therapeutics, Inc. (AKBA) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Confident tone
Vafcio launch performance
Observed dosing protocol adoption
Perlisiguat / FSGS pipeline
Revenue
$53.54M
▼ 6.6% YoY Diluted EPS
$-0.03
▼ 200% YoY Gross margin
77.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
Positive tone
Vafseo Commercial Launch
Q4 2025 Demand Softness
Post-Marketing Studies (VOCAL/VOICE)
Revenue
$57.62M*
▲ 23.9% YoY Gross margin
78.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript
Positive tone
Dialysis provider partnerships and access expansion
Operational and adherence challenges
Clinical data and standard of care goal
Revenue
$58.77M
▲ 57% YoY Diluted EPS
$0.00
Gross margin
84.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript
Confident tone
Vafseo launch progress
Auryxia legacy franchise and generic risk
DaVita and large dialysis provider access
Revenue
$62.47M
▲ 43.1% YoY Diluted EPS
$0.00
Gross margin
84.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript
Confident tone
Dialysis organization onboarding and large-provider pilots
Vafseo (vadadustat) US launch and net product revenues
Refills, persistence, and dose titration
Revenue
$57.34M
▲ 75.8% YoY Diluted EPS
$0.03
Gross margin
86.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript
Confident tone
Vafseo U.S. launch performance
Reimbursement mix (Medicare, Medicare Advantage, commercial)
Dialysis organization access and contracting
Revenue
$46.50M*
▼ 17.3% YoY Gross margin
56.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript
Confident tone
Vafseo launch preparation
Dialysis contracting and access
Prescriber demand and awareness
Revenue
$37.43M
▼ 11% YoY Diluted EPS
$-0.10
Gross margin
62.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call
Revenue
$43.65M
▼ 22.6% YoY Diluted EPS
$-0.04
Gross margin
60.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript
Confident tone
Vafseo launch execution
Auryxia entering the bundle
Clinical data and publications
Revenue
$32.61M
▼ 18.5% YoY Diluted EPS
$-0.09
Gross margin
64.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Akebia Therapeutics, Inc. (AKBA) Q4 2023 Earnings Call
Revenue
$56.20M*
▲ 0.9% YoY Gross margin
66.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Akebia Therapeutics, Inc. (AKBA) Q3 2023 Earnings Call Transcript
Revenue
$42.05M
▼ 13.7% YoY Diluted EPS
$-0.08
Gross margin
57.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-25
Akebia Therapeutics, Inc. (AKBA) Q2 2023 Earnings Call Transcript
Revenue
$56.38M
▼ 55.4% YoY Diluted EPS
$-0.06
▼ 140% YoY Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Akebia Therapeutics, Inc. (AKBA) Q1 2023 Earnings Call Transcript
Revenue
$40.01M
▼ 35.2% YoY Diluted EPS
$-0.15
Gross margin
49.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Akebia Therapeutics, Inc. (AKBA) Q4 2022 Earnings Call Transcript
Revenue
$55.71M*
▼ 3.4% YoY Gross margin
104.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Akebia Therapeutics, Inc. (AKBA) Q3 2022 Earnings Call Transcript
Revenue
$48.71M
▼ 0.1% YoY Diluted EPS
$-0.29
Gross margin
21.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Akebia Therapeutics, Inc. (AKBA) Q2 2022 Earnings Call Transcript
Revenue
$126.36M
▲ 138.8% YoY Diluted EPS
$0.15
Gross margin
85.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Akebia Therapeutics, Inc. (AKBA) Q1 2022 Earnings Call Transcript
Revenue
$61.70M
▲ 18% YoY Diluted EPS
$-0.35
Gross margin
49.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q3
2021-11-04
Akebia Therapeutics, Inc. (AKBA) Q3 2021 Earnings Call Transcript
Revenue
$48.76M
▼ 18.7% YoY Diluted EPS
$-0.34
Gross margin
67.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Akebia Therapeutics, Inc. (AKBA) Q2 2021 Earnings Call Transcript
Revenue
$52.91M
▼ 41.3% YoY Diluted EPS
$-0.51
Gross margin
0.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Akebia Therapeutics, Inc. (AKBA) Q1 2021 Earnings Call Transcript
Revenue
$52.30M
▼ 40.9% YoY Diluted EPS
$-0.45
Gross margin
33.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Akebia Therapeutics, Inc. (AKBA) Q4 2020 Earnings Call Transcript
Revenue
$56.04M*
▼ 19.4% YoY Gross margin
-12.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Akebia Therapeutics, Inc. (AKBA) Q3 2020 Earnings Call Transcript
Revenue
$59.99M
▼ 34.8% YoY Diluted EPS
$-0.42
Gross margin
49.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Akebia Therapeutics, Inc. (AKBA) Q2 2020 Earnings Call
Revenue
$90.14M
▼ 10.6% YoY Diluted EPS
$-1.28
Gross margin
-93.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Akebia Therapeutics, Inc. (AKBA) Q1 2020 Earnings Call Transcript
Revenue
$88.48M
▲ 21.8% YoY Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-10
Akebia Therapeutics, Inc. (AKBA) Q4 2019 Earnings Call
Revenue
$69.56M*
▲ 16.2% YoY Gross margin
45.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 webcasts
Key facts
CIK
1517022
CUSIP
00972D105
13F (30d)
157 filings
140 filers
Visit website
Investor relations